BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37654647)

  • 1. Anti-IL5 Monoclonal Antibodies Reduce Asthma Exacerbations and Corticosteroids Dose in Three Eosinophilic Granulomatosis with Polyangiitis Case Reports.
    Skouvaklidou E; Kipourou M; Zisopoulos D; Vounotrypidis P; Katsoulis K
    Mediterr J Rheumatol; 2023 Jun; 34(2):238-244. PubMed ID: 37654647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis.
    Matsuno O; Minamoto S
    Respir Med Case Rep; 2022; 40():101763. PubMed ID: 36353062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of anti-eosinophilic therapies in eosinophilic granulomatosis with polyangiitis: a systematic review.
    Kouverianos I; Angelopoulos A; Daoussis D
    Rheumatol Int; 2023 Jul; 43(7):1245-1252. PubMed ID: 37085573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis.
    Guntur VP; Manka LA; Denson JL; Dunn RM; Dollin YT; Gill M; Kolakowski C; Strand MJ; Wechsler ME
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1186-1193.e1. PubMed ID: 33065367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
    Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
    Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis.
    Koga Y; Aoki-Saito H; Kamide Y; Sato M; Tsurumaki H; Yatomi M; Ishizuka T; Hisada T
    Front Pharmacol; 2022; 13():865318. PubMed ID: 35359852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis.
    Desaintjean C; Ahmad K; Traclet J; Gerfaud-Valentin M; Durel CA; Glerant JC; Hot A; Lestelle F; Mainbourg S; Nasser M; Seve P; Turquier S; Devouassoux G; Cottin V
    Front Med (Lausanne); 2024; 11():1341310. PubMed ID: 38585151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benralizumab in the management of rare primary eosinophilic lung diseases.
    Griscti Soler D; Bennici A; Brunetto S; Gangemi S; Ricciardi L
    Allergy Asthma Proc; 2022 Nov; 43(6):494-500. PubMed ID: 36335418
    [No Abstract]   [Full Text] [Related]  

  • 9. [Benralizumab in cases of eosinophilic granulomatosis with polyangiitis].
    Carrette A; Mercier V; Lelubre C; Peché R
    Rev Mal Respir; 2022 Sep; 39(7):621-625. PubMed ID: 35909008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab.
    Menzella F; Galeone C; Ghidoni G; Ruggiero P; Capobelli S; Simonazzi A; Catellani C; Scelfo C; Livrieri F; Facciolongo N
    Multidiscip Respir Med; 2021 Jan; 16(1):779. PubMed ID: 34221399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy.
    Faverio P; Bonaiti G; Bini F; Vaghi A; Pesci A
    Ther Clin Risk Manag; 2018; 14():2385-2396. PubMed ID: 30573961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early add-on administration of mepolizumab and intravenous immunoglobulin effective in treating eosinophilic granulomatosis with polyangiitis.
    Ikeda T; Komatsu T; Yokoyama K; Takahashi K; Kawakami T
    J Dermatol; 2021 Apr; 48(4):529-532. PubMed ID: 33305381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?
    Vergles M; Matković Z; Lalić K; Trkanjec JT; Tudorić N
    J Asthma; 2021 Dec; 58(12):1675-1679. PubMed ID: 32962455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
    Hillas G; Fouka E; Papaioannou AI
    Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
    [No Abstract]   [Full Text] [Related]  

  • 15. Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab.
    Ricciardi L; Soler DG; Bennici A; Brunetto S; Pioggia G; Gangemi S
    Front Pharmacol; 2022; 13():858344. PubMed ID: 35462932
    [No Abstract]   [Full Text] [Related]  

  • 16. Torasemide-induced Vascular Purpura in the Course of Eosinophilic Granulomatosis with Polyangiitis.
    Frątczak A; Polak K; Miziołek B; Bergler-Czop B
    Acta Dermatovenerol Croat; 2022 Sep; 30(2):116-118. PubMed ID: 36254546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of monoclonal antibodies targeting type 2 inflammation for severe asthma and eosinophilic granulomatosis with polyangiitis.
    Davanzo F; Marchi MR; Iorio L; Bortoli M; Doria A; Padoan R
    Autoimmun Rev; 2024 Mar; 23(3):103503. PubMed ID: 38101691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from omalizumab to mepolizumab therapy improved extra-pulmonary abdominal and cutaneous vasculitis symptoms in a patient with eosinophilic granulomatosis with polyangiitis.
    Chen YH; Kuo PH
    Respirol Case Rep; 2022 Jan; 10(1):e0878. PubMed ID: 34876987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
    McBrien CN; Menzies-Gow A
    Drugs Today (Barc); 2018 Feb; 54(2):93-101. PubMed ID: 29637936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [SUCCESSFUL TREATMENT FOR OTITIS MEDIA AND SINUSITIS ASSOCIATED WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS USING ANTI-IL-5 RECEPTOR MONOCLONAL ANTIBODY BENRALIZUMAB].
    Sugiyama T; Yoshida S; Kikuchi S; Iino Y
    Arerugi; 2022; 71(3):242-247. PubMed ID: 35569946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.